{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:47:22Z","timestamp":1793292442793,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer&apos;s Drug Discovery Foundation","doi-asserted-by":"publisher","award":["GC-201808-2016354"],"award-info":[{"award-number":["GC-201808-2016354"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","award":["CT190002"],"award-info":[{"award-number":["CT190002"]}],"id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.inpsyc.2026.100183","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:28:04Z","timestamp":1768249684000},"page":"100183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of clinical factors that predict response to nabilone for agitation in Alzheimer\u2019s disease: A post hoc analysis of a randomized placebo-controlled trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-133X","authenticated-orcid":false,"given":"Oriel J.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-6110","authenticated-orcid":false,"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-2593","authenticated-orcid":false,"given":"Myuri","family":"Ruthirakuhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas Paul","family":"L.G. Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.inpsyc.2026.100183_bib1","doi-asserted-by":"crossref","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & Dementia. 2020;16(3):391-460. doi:10.1002\/alz.12068.","DOI":"10.1002\/alz.12068"},{"issue":"9","key":"10.1016\/j.inpsyc.2026.100183_bib2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1017\/S1041610218001898","article-title":"Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course","volume":"31","author":"Anatchkova","year":"2019","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: international psychogeriatric association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.inpsyc.2026.100183_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.trci.2019.10.004","article-title":"Institutionalization risk and costs associated with agitation in Alzheimer\u2019s disease","volume":"5","author":"Cloutier","year":"2019","journal-title":"Alzheimers Dement (N Y"},{"issue":"2","key":"10.1016\/j.inpsyc.2026.100183_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3233\/JAD-215670","article-title":"The impact of agitation in dementia on caregivers: a real-world survey","volume":"88","author":"Schein","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"22","key":"10.1016\/j.inpsyc.2026.100183_bib6","first-page":"1907","article-title":"FDA greenlights first drug for agitation related to Alzheimer disease","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11920-015-0640-7","article-title":"Agitation and irritability in Alzheimer\u2019s disease: evidenced-based treatments and the black box warning","volume":"18","author":"Koenig","year":"2016","journal-title":"Curr Psychiatry Rep"},{"issue":"6","key":"10.1016\/j.inpsyc.2026.100183_bib8","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m14791","article-title":"The Use of Dispensary-Obtained Tetrahydrocannabinol as a Treatment for Neuropsychiatric Symptoms of Dementia","volume":"84","author":"Sawicki","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.inpsyc.2026.100183_bib9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jagp.2021.01.015","article-title":"Cannabinoids for agitation in Alzheimer\u2019s disease","volume":"29","author":"Outen","year":"2021","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"10.1016\/j.inpsyc.2026.100183_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.inpsyc.2026.100183_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003524","article-title":"Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: a systematic review and meta-analysis","volume":"18","author":"Velayudhan","year":"2021","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.inpsyc.2026.100183_bib12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/alz.12335","article-title":"Agitation in Alzheimer\u2019s disease: novel outcome measures reflecting the international psychogeriatric association (IPA) agitation criteria","volume":"17","author":"De Mauleon","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.inpsyc.2026.100183_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000417403","article-title":"Agitation in the elderly","volume":"19","author":"Cohen-Mansfield","year":"1989","journal-title":"Adv Psychosom Med"},{"issue":"3","key":"10.1016\/j.inpsyc.2026.100183_bib14","doi-asserted-by":"crossref","first-page":"M77","DOI":"10.1093\/geronj\/44.3.M77","article-title":"A description of agitation in a nursing home","volume":"44","author":"Cohen-Mansfield","year":"1989","journal-title":"J Gerontol"},{"key":"10.1016\/j.inpsyc.2026.100183_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100385","article-title":"Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer\u2019s disease: study protocol for a cross-over randomized controlled trial","volume":"15","author":"Ruthirakuhan","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.inpsyc.2026.100183_bib16","doi-asserted-by":"crossref","unstructured":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. American psychiatric association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"S4","key":"10.1016\/j.inpsyc.2026.100183_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.1998.tb00444.x","article-title":"An integrated approach to the management of Alzheimer\u2019s disease: assessing cognition, function and behaviour","volume":"5","author":"Galasko","year":"1998","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1017\/S1041610297004754","article-title":"A guide to the standardized mini-mental state examination","volume":"9","author":"Molloy","year":"1997","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.inpsyc.2026.100183_bib19","unstructured":"Cummings J.L. Neuropsychiatric Inventory Nursing Home Version (NPI-NH). Published online 1994."},{"issue":"2","key":"10.1016\/j.inpsyc.2026.100183_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0891988719882102","article-title":"The neuropsychiatric inventory: development and applications","volume":"33","author":"Cummings","year":"2020","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.JAM.0000043422.31640.F7","article-title":"Development and psychometric evaluation of the pain assessment in advanced dementia (PAINAD) scale","volume":"4","author":"Warden","year":"2003","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"10.1016\/j.inpsyc.2026.100183_bib22","doi-asserted-by":"crossref","first-page":"M366","DOI":"10.1093\/gerona\/56.6.M366","article-title":"Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF)","volume":"56","author":"Rubenstein","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"10.1016\/j.inpsyc.2026.100183_bib23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jagp.2023.06.002","article-title":"Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 trial","volume":"31","author":"Lanct\u00f4t","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.inpsyc.2026.100183_bib24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1176\/appi.ajp.2015.15050648","article-title":"Heterogeneity of treatment response to citalopram for Alzheimer disease patients with aggression or agitation: the CitAD randomized clinical trial","volume":"173","author":"Schneider","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.inpsyc.2026.100183_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17582024.2025.2587549","article-title":"Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer\u2019s disease \u2013 an exploratory post hoc analysis","author":"Wang","year":"2025","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"10.1016\/j.inpsyc.2026.100183_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3233\/JAD-180641","article-title":"Neuropsychiatric inventory in community-dwelling older adults with mild cognitive impairment and dementia","volume":"68","author":"Nunes","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.inpsyc.2026.100183_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3945\/ajcn.113.068122","article-title":"BMI and all-cause mortality in older adults: a meta-analysis123","volume":"99","author":"Winter","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.inpsyc.2026.100183_bib28","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.neuroimage.2018.10.013","article-title":"Sex difference in brain CB1 receptor availability in man","volume":"184","author":"Laurikainen","year":"2019","journal-title":"Neuroimage"},{"issue":"9","key":"10.1016\/j.inpsyc.2026.100183_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3928\/00989134-20090731-01","article-title":"Psychotropic medication use among older adults: what all nurses need to know","volume":"35","author":"Lindsey","year":"2009","journal-title":"J Gerontol Nurs"},{"issue":"6","key":"10.1016\/j.inpsyc.2026.100183_bib30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J Anesth"},{"issue":"12","key":"10.1016\/j.inpsyc.2026.100183_bib31","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1017\/S1041610215001106","article-title":"Change in agitation in Alzheimer\u2019s disease in the placebo arm of a 9-week controlled trial","volume":"27","author":"Rosenberg","year":"2015","journal-title":"Int Psychogeriatr"},{"issue":"12","key":"10.1016\/j.inpsyc.2026.100183_bib32","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.inpsyc.2026.100183_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000241878","article-title":"Mini-mental state examination is sensitive to brain atrophy in Alzheimer\u2019s disease","volume":"28","author":"Fjell","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8","key":"10.1016\/j.inpsyc.2026.100183_bib34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuint.2010.10.010","article-title":"Intact cannabinoid CB1 receptors in the Alzheimer\u2019s disease cortex","volume":"57","author":"Lee","year":"2010","journal-title":"Neurochem Int"},{"issue":"3","key":"10.1016\/j.inpsyc.2026.100183_bib35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3233\/JAD-140492","article-title":"R. Type-1 cannabinoid receptor activity during Alzheimer\u2019s disease progression","volume":"42","author":"Manuel","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.inpsyc.2026.100183_bib36","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer\u2019s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ram\u00edrez","year":"2005","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib37","article-title":"Pain in dementia","volume":"5","author":"Achterberg","year":"2019","journal-title":"Pain Rep"},{"issue":"8","key":"10.1016\/j.inpsyc.2026.100183_bib38","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/j.pain.0000000000000195","article-title":"Experimental pain processing in individuals with cognitive impairment: current state of the science","volume":"156","author":"Defrin","year":"2015","journal-title":"PAIN"},{"issue":"12","key":"10.1016\/j.inpsyc.2026.100183_bib39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40266-014-0222-0","article-title":"Effective pain management in patients with dementia: benefits beyond pain?","volume":"31","author":"Flo","year":"2014","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12877-015-0048-6","article-title":"Association between pain, neuropsychiatric symptoms, and physical function in dementia: a systematic review and meta-analysis","volume":"15","author":"van Dalen-Kok","year":"2015","journal-title":"BMC Geriatr"},{"issue":"3","key":"10.1016\/j.inpsyc.2026.100183_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/phar.1709","article-title":"Nabilone for the management of pain","volume":"36","author":"Tsang","year":"2016","journal-title":"Pharm J Hum Pharmacol Drug Ther"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjp.0704466","article-title":"Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat","volume":"135","author":"Conti","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00019442-200002000-00010","article-title":"The use of the neuropsychiatric inventory in nursing home residents. characterization and measurement","volume":"8","author":"Wood","year":"2000","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.inpsyc.2026.100183_bib44","doi-asserted-by":"crossref","unstructured":"Lee H.H., Chinnameyyappan A., Feldman O.J., Marotta G., Survilla K., Lanct\u00f4t K.L. Behavioral and Psychological Symptoms (BPSD) in Alzheimer\u2019s Disease (AD): Development and Treatment. Curr Top Behav Neurosci. Published online January 25, 2025. doi:10.1007\/7854_2024_566.","DOI":"10.1007\/7854_2024_566"},{"issue":"5","key":"10.1016\/j.inpsyc.2026.100183_bib45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1755-5949.2010.00161.x","article-title":"The role of dopamine in symptoms and treatment of apathy in Alzheimer\u2019s disease","volume":"17","author":"Mitchell","year":"2011","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"10.1016\/j.inpsyc.2026.100183_bib46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/bjp.2008.130","article-title":"The endocannabinoid system in brain reward processes","volume":"154","author":"Solinas","year":"2008","journal-title":"Br J Pharm"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/npp.2017.126","article-title":"Endocannabinoid regulation of reward and reinforcement through interaction with dopamine and endogenous opioid signaling","volume":"43","author":"Wenzel","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-pharmtox-010716-104615","article-title":"Don\u2019t worry, be happy: endocannabinoids and cannabis at the intersection of stress and reward","volume":"57","author":"Volkow","year":"2017","journal-title":"Annu Rev Pharm Toxicol"},{"issue":"7","key":"10.1016\/j.inpsyc.2026.100183_bib49","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/10826084.2020.1729203","article-title":"A comprehensive examination of the links between cannabis use and motivation","volume":"55","author":"Petrucci","year":"2020","journal-title":"Subst Use Misuse"},{"issue":"11","key":"10.1016\/j.inpsyc.2026.100183_bib50","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00213-014-3523-4","article-title":"The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study","volume":"231","author":"Bloomfield","year":"2014","journal-title":"Psychopharmacol (Berl)"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ijnp\/pyac056","article-title":"Anhedonia, apathy, pleasure, and effort-based decision-making in adult and adolescent cannabis users and controls","volume":"26","author":"Skumlien","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.inpsyc.2026.100183_bib52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1747-597X-1-2","article-title":"Cannabis, motivation, and life satisfaction in an internet sample","volume":"1","author":"Barnwell","year":"2006","journal-title":"Subst Abus Treat Prev Policy"},{"key":"10.1016\/j.inpsyc.2026.100183_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuropharm.2018.01.021","article-title":"Cannabinoids induce apathetic and impulsive patterns of choice through CB1 receptors and TRPV1 channels","volume":"133","author":"Fatahi","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.inpsyc.2026.100183_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2020.604488","article-title":"Eating behavior in aging and dementia: the need for a comprehensive assessment","volume":"7","author":"Fostinelli","year":"2020","journal-title":"Front Nutr"},{"issue":"8","key":"10.1016\/j.inpsyc.2026.100183_bib55","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/1533317516673155","article-title":"Eating behaviors and dietary changes in patients with dementia","volume":"31","author":"Cipriani","year":"2016","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"5","key":"10.1016\/j.inpsyc.2026.100183_bib56","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nn1457","article-title":"Endocannabinoid control of food intake and energy balance","volume":"8","author":"Di Marzo","year":"2005","journal-title":"Nat Neurosci"},{"issue":"9","key":"10.1016\/j.inpsyc.2026.100183_bib57","first-page":"3029","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.inpsyc.2026.100183_bib58","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/archneur.56.11.1388","article-title":"The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease","volume":"56","author":"Mega","year":"1999","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.inpsyc.2026.100183_bib59","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40266-023-01065-x","article-title":"Psychiatric adverse events of acetylcholinesterase inhibitors in Alzheimer\u2019s disease and Parkinson\u2019s dementia: systematic review and meta-analysis","volume":"40","author":"Bittner","year":"2023","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100183_bib60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000524086","article-title":"Inhibitory effects of cannabinoids on acetylcholinesterase and butyrylcholinesterase enzyme activities","volume":"5","author":"Puopolo","year":"2022","journal-title":"Med Cannabis Cannabinoids"},{"key":"10.1016\/j.inpsyc.2026.100183_bib61","series-title":"Cholinesterase inhibitors","author":"Singh","year":"2025"},{"issue":"5","key":"10.1016\/j.inpsyc.2026.100183_bib62","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1517\/14740338.3.5.425","article-title":"The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer\u2019s disease","volume":"3","author":"Thompson","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.inpsyc.2026.100183_bib63","unstructured":"International Psychogeriatric Association, ed. The IPA Complete Guides to Behavioral and Psychological Symptoms of Dementia (BPSD): Specialists Guide. International Psychogeriatric Association; 2015. Accessed May 13, 2025. \u3008https:\/\/www.ipa-online.org\/UserFiles\/file\/IPA_BPSD_Specialists_Complete_Guide_Online_2015_Final.pdf\u3009."},{"issue":"7","key":"10.1016\/j.inpsyc.2026.100183_bib64","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/sim.1687","article-title":"Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses","volume":"23","author":"Austin","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.inpsyc.2026.100183_bib65","unstructured":"Sunnybrook Health Sciences Centre. Nabilone for Agitation Blinded Intervention Trial. clinicaltrials.gov; 2025. Accessed May 15, 2025. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04516057\u3009."}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610226000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610226000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:17:12Z","timestamp":1777605432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610226000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":65,"alternative-id":["S1041610226000013"],"URL":"https:\/\/doi.org\/10.1016\/j.inpsyc.2026.100183","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of clinical factors that predict response to nabilone for agitation in Alzheimer\u2019s disease: A post hoc analysis of a randomized placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.inpsyc.2026.100183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Psychogeriatric Association.","name":"copyright","label":"Copyright"}],"article-number":"100183"}}